Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
ImmunityBio, Inc. clinical trials
Also known as NantKwest, Conkwest.
The registry lists 115 studies whose lead sponsor is ImmunityBio, Inc. or one of 3 companies grouped under it. 15 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2026.
Keep track of what changes. Save the ImmunityBio, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to ImmunityBio, Inc..
- ImmunityBio, Inc.83 studiesSame company
Something wrong?
- 15 studies →
- 13 studies →
- 4 studies →
Focus areas
Conditions ImmunityBio, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 115. Browse all 115 →
- NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With SepsisNot yet recruitingNCT07783789Phase 2
- N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNot yet recruitingNCT07217496Phase 1
- A Study to Examine Anktiva for the Treatment of COVID-19.RecruitingNCT07123727Phase 2
- Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint InRecruitingNCT06745908Phase 3
- A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerRecruitingNCT06710288Phase 2
- Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard ChemoradiationNot yet recruitingNCT07628062Phase 2
- ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder CancerAvailableNCT06810141
- A Study to Assess Anktiva in Patients With Long Covid-19.RecruitingNCT07108036Phase 2
- NAI for Sepsis With Persistent LymphopeniaNot yet recruitingNCT07578558Phase 2
- Study of Relapsed/ Refractory B-cell Non- Hodgkin LymphomaRecruitingNCT07125872Phase 2
- Study for Subjects With Relapsed/Refractory Non- Hodgkin LymphomaRecruitingNCT05618925Phase 1
- ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCGRecruitingNCT06800963Phase 1/2
- Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNot yet recruitingNCT07477366Phase 2
- Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerNot yet recruitingNCT06829823Phase 2
- Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation TherapyAvailableNCT06956547
- QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic MelanomaTerminatedNCT01029873Phase 1/2
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- IBRX-042 In Participants With HPV-Associated TumorsActive, not recruitingNCT05976828Phase 1
- Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic CancerWithdrawnNCT07488884Phase 1
- A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic LeukemiaTerminatedNCT07556757Phase 1
- Study for Participants With Relapsed/Refractory Non-Hodgkin LymphomaActive, not recruitingNCT06334991Phase 1
- N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaActive, not recruitingNCT06061809Phase 2
- Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLCWithdrawnNCT07524257Phase 3
- Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerTerminatedNCT03520686Phase 3
- ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder CancerWithdrawnNCT07551544Phase 3
- Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired PneumoniaWithdrawnNCT07492875Phase 3
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)WithdrawnNCT07492888Phase 2
- Immunotherapy Before and After SurgeryWithdrawnNCT06765902Phase 2
- Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.WithdrawnNCT06765954Phase 2
- Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)Active, not recruitingNCT05981131
- HCW9218 for Advanced Pancreatic CancerCompletedNCT05304936Phase 1/2
- QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid CancersCompletedNCT04050709Phase 1
- A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerActive, not recruitingNCT02138734Phase 1/2
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
- Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT04390399Phase 2
- QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT04898543Phase 1
- QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEACompletedNCT01147965Phase 1/2
Sponsor listed in the registry: NantCell, Inc. · First submitted before NantCell, Inc. became part of ImmunityBio, Inc.
- QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerActive, not recruitingNCT03022825Phase 2/3
- Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By ApheresisCompletedNCT06040918Phase 1
- QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803CompletedNCT03381586Phase 1
Sponsor listed in the registry: Altor BioScience · First submitted before Altor BioScience became part of ImmunityBio, Inc.
- THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 VaccinesTerminatedNCT05370040Phase 1/2
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03169764Phase 1/2
- QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLWithdrawnNCT03169790Phase 1/2
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnNCT03175666Phase 1/2
- COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based VaccinesWithdrawnNCT04845191Phase 1/2
- QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnNCT03563144Phase 2
- COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based VaccinesWithdrawnNCT04843722Phase 1/2
- QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerWithdrawnNCT03574649Phase 2
- QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.WithdrawnNCT03647423Phase 1/2
- QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyWithdrawnNCT03167164Phase 1/2
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnNCT03197584Phase 1/2